Company Filing History:
Years Active: 2024
Title: Karyn Schmidt: Innovator in RNAi Therapeutics
Introduction
Karyn Schmidt is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of RNA interference (RNAi) therapeutics. With a focus on innovative solutions for genetic disorders, she has made strides in developing targeted therapies that address critical health issues.
Latest Patents
Karyn Schmidt holds a patent for her invention titled "Factor XII (F12) iRNA compositions and methods of use thereof." This patent relates to RNAi agents, specifically double-stranded RNA (dsRNA) agents that target the Factor XII (F12) gene. The invention outlines methods for using these RNAi agents to inhibit the expression of the F12 gene, which can be pivotal in preventing and treating various F12-associated disorders. These disorders include hereditary angioedema (HAE), prekallikrein deficiency, malignant essential hypertension, hypertension, end-stage renal disease, Fletcher Factor Deficiency, thromboembolic disease, inflammatory disease, and Alzheimer's Disease.
Career Highlights
Karyn Schmidt is currently employed at Alnylam Pharmaceuticals, Inc., where she continues to advance her research in RNAi technologies. Her work is instrumental in the development of therapies that can significantly improve patient outcomes for those suffering from genetic disorders.
Collaborations
Throughout her career, Karyn has collaborated with notable colleagues, including Mark K Schlegel and Adam Castoreno. These partnerships have fostered a collaborative environment that enhances innovation and research in the field of RNAi therapeutics.
Conclusion
Karyn Schmidt's contributions to RNAi therapeutics exemplify her commitment to advancing medical science and improving patient care. Her innovative work in targeting the Factor XII gene showcases the potential of RNAi technology in treating complex genetic disorders.